IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 310 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,624 | +102.0% | 35,812 | +82.7% | 0.00% | 0.0% |
| Q2 2023 | $804 | +14.7% | 19,604 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $701 | -5.3% | 19,604 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $740 | -99.9% | 19,604 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $867,000 | +19.4% | 19,604 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $726,000 | 0.0% | 19,604 | 0.0% | 0.00% | +33.3% |
| Q1 2022 | $726,000 | +21.6% | 19,604 | 0.0% | 0.00% | +50.0% |
| Q4 2021 | $597,000 | -9.3% | 19,604 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $658,000 | -15.9% | 19,604 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $782,000 | -11.2% | 19,604 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $881,000 | -20.5% | 19,604 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $1,108,000 | +19.1% | 19,604 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $930,000 | -19.6% | 19,604 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $1,156,000 | +24.7% | 19,604 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $927,000 | -21.6% | 19,604 | +0.2% | 0.01% | -14.3% |
| Q4 2019 | $1,182,000 | +0.9% | 19,566 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $1,172,000 | -6.8% | 19,566 | 0.0% | 0.01% | -12.5% |
| Q2 2019 | $1,258,000 | -20.8% | 19,566 | 0.0% | 0.01% | -20.0% |
| Q1 2019 | $1,588,000 | +21.8% | 19,566 | -18.9% | 0.01% | +11.1% |
| Q4 2018 | $1,304,000 | +4.6% | 24,121 | -0.2% | 0.01% | +12.5% |
| Q3 2018 | $1,247,000 | +23.7% | 24,173 | -0.1% | 0.01% | +14.3% |
| Q2 2018 | $1,008,000 | -5.7% | 24,197 | -0.2% | 0.01% | 0.0% |
| Q1 2018 | $1,069,000 | -15.6% | 24,244 | -3.7% | 0.01% | -12.5% |
| Q4 2017 | $1,266,000 | +2.3% | 25,177 | +3.2% | 0.01% | -11.1% |
| Q3 2017 | $1,237,000 | -0.3% | 24,391 | +0.0% | 0.01% | 0.0% |
| Q2 2017 | $1,241,000 | +26.9% | 24,390 | +0.3% | 0.01% | +28.6% |
| Q1 2017 | $978,000 | -19.0% | 24,325 | -3.6% | 0.01% | -30.0% |
| Q4 2016 | $1,207,000 | +25.2% | 25,228 | -4.1% | 0.01% | +25.0% |
| Q3 2016 | $964,000 | +48.8% | 26,316 | -5.4% | 0.01% | +60.0% |
| Q2 2016 | $648,000 | -42.5% | 27,817 | +0.1% | 0.01% | -44.4% |
| Q1 2016 | $1,126,000 | -37.4% | 27,794 | -4.4% | 0.01% | -40.0% |
| Q4 2015 | $1,800,000 | – | 29,062 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |